J. Ottaway

1.6k total citations
11 papers, 1.1k citations indexed

About

J. Ottaway is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. Ottaway has authored 11 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in J. Ottaway's work include Breast Cancer Treatment Studies (3 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). J. Ottaway is often cited by papers focused on Breast Cancer Treatment Studies (3 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Research Studies (3 papers). J. Ottaway collaborates with scholars based in Canada and United States. J. Ottaway's co-authors include Kathleen I. Pritchard, Mark N. Levine, Dongsheng Tu, Lois E. Shepherd, Benny Zee, Ted Vandenberg, B. Findlay, Robert G. MacKenzie, B. Norris and V. Bramwell and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

J. Ottaway

11 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Ottaway Canada 7 875 466 312 147 138 11 1.1k
Joanna Dewar Australia 12 514 0.6× 228 0.5× 393 1.3× 117 0.8× 37 0.3× 23 970
F J Cummings United States 20 691 0.8× 300 0.6× 159 0.5× 116 0.8× 70 0.5× 35 1.2k
Naveen Faridi Pakistan 24 570 0.7× 345 0.7× 265 0.8× 185 1.3× 137 1.0× 85 1.4k
R. Largillier France 14 940 1.1× 527 1.1× 334 1.1× 162 1.1× 88 0.6× 47 1.5k
J. F. Pringle Canada 18 480 0.5× 247 0.5× 310 1.0× 155 1.1× 379 2.7× 22 1.3k
Lalao Randimbison Switzerland 26 1.1k 1.2× 274 0.6× 345 1.1× 165 1.1× 767 5.6× 62 1.8k
Miso Kim South Korea 25 1.2k 1.4× 208 0.4× 710 2.3× 292 2.0× 107 0.8× 87 1.7k
Josiane Otto France 20 1.1k 1.3× 259 0.6× 906 2.9× 228 1.6× 98 0.7× 59 1.6k
Sandra J. Casak United States 18 455 0.5× 107 0.2× 215 0.7× 171 1.2× 109 0.8× 32 1.0k
Daniel Serin France 17 1.3k 1.4× 808 1.7× 242 0.8× 75 0.5× 40 0.3× 45 1.6k

Countries citing papers authored by J. Ottaway

Since Specialization
Citations

This map shows the geographic impact of J. Ottaway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Ottaway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Ottaway more than expected).

Fields of papers citing papers by J. Ottaway

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Ottaway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Ottaway. The network helps show where J. Ottaway may publish in the future.

Co-authorship network of co-authors of J. Ottaway

This figure shows the co-authorship network connecting the top 25 collaborators of J. Ottaway. A scholar is included among the top collaborators of J. Ottaway based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Ottaway. J. Ottaway is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
2.
Parulekar, Wendy R., Andrew G. Day, J. Ottaway, et al.. (2005). Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. Journal of Clinical Oncology. 23(25). 6002–6008. 105 indexed citations
6.
El‐Sayed, Samy, Abdenour Nabid, Robert G. MacKenzie, et al.. (2000). Prophylaxis of radiation associated mucositis (RAM) in head and neck cancer, results of a double blind phase III trail evaluating the clinical efficacy of an antimicrobial lozenge utilizing a new validated mucositis scoring system. International Journal of Radiation Oncology*Biology*Physics. 48(3). 321–321. 2 indexed citations
7.
Murray, Nevin, Robert B. Livingston, Frances A. Shepherd, et al.. (1999). Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. Journal of Clinical Oncology. 17(8). 2300–2300. 87 indexed citations
8.
Payne, David G., Ronald L. Burkes, J Deslauriers, et al.. (1998). Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. British Journal of Cancer. 78(5). 683–685. 52 indexed citations
10.
Goss, Paul E., Karen Gelmon, Leona Rudinskas, et al.. (1997). Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 41(1). 53–60. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026